Sequential use of letrozole and gonadotrophin in women with poor ovarian reserve – a randomized controlled trial

Vivian Chi Yan LEE† (FHKAM(OG))
Carina Chi Wai Chan (FHKAM(OG))
Ernest Hung Yu NG (MD, FRCOG, FHKAM(OG))
William Shu Biu YEUNG (PhD)
Pak Chung HO (MD, FRCOG, FHKAM(OG))

Department of Obstetrics & Gynecology
The University of Hong Kong
Hong Kong Special Administrative Region
People’s Republic of China

This study was supported by the Hong Kong OG Trust Fund.

†To whom correspondence should be addressed
Department of Obstetrics and Gynecology,
The University of Hong Kong,
Queen Mary Hospital,
Pokfulam Road, Hong Kong
Telephone: 852-22553400
Fax: 852-28175374
E-mail: v200lee@hku.hk
Abstract

This randomized trial compared the sequential use of letrozole and gonadotrophin (HMG) with HMG only in poor ovarian responders undergoing IVF. Patients with < four oocytes retrieved in previous IVF cycles or < 5 antral follicles were randomized to either letrozole for 5 days followed by HMG or HMG alone. 53 women were recruited. The letrozole group had significantly lower dosage of HMG ($P < 0.001$), shorter duration of HMG ($P < 0.001$) and fewer oocytes ($P = 0.001$) when compared to the control group. Live-birth rate was comparable with a significantly lower miscarriage rate in the letrozole group ($P = 0.038$). Serum FSH concentrations were comparable in both groups except on Day 8, while estradiol concentrations were all significantly lower in the letrozole group from day 4. Follicular fluid concentrations of testosterone, androstenedione, FSH and AMH were significantly higher in the letrozole group ($P = 0.009$, $P = 0.001$, $P = 0.046$ and $P = 0.034$ respectively). When compared to HMG alone, sequential use of letrozole and HMG in poor responders resulted in significantly lower total dosage and shorter duration of HMG, a comparable live-birth rate, a significantly lower miscarriage rate but a more favourable hormonal environment of follicular fluid.

Keywords: follicular fluid; in-vitro fertilization; letrozole; live-birth rate; poor ovarian responders


**Introduction**

*In vitro* fertilization (IVF) is an effective treatment for various causes of subfertility. It involves ovarian stimulation for multiple follicular development, oocyte retrieval and embryo transfer after fertilization. Multiple embryos are usually transferred to compensate for their low implantation potential, which has remained steady at 20-25%, despite recent advances in ovarian stimulation, gamete handling, assisted fertilization and embryo culture. The success of embryo cryopreservation also makes it desirable to obtain multiple embryos to allow an increased number of embryo transfers, thus increasing the cumulative pregnancy rates (Wang et al. 1994).

Therefore, the development of multiple follicles in response to gonadotrophin stimulation is usually considered as one of the key factors leading to a successful outcome. Poor ovarian response has usually been associated with low pregnancy rates and many of these cycles are cancelled without proceeding to oocyte retrieval (Keay et al. 1997). The management of poor ovarian responders has been extensively reviewed (Keay et al. 1997; Karande and Gleicher 1999; Fasouliotis et al. 2000; Surrey and Schoolcraft 2000; Mahutte and Arici 2002; Tarlatzis et al. 2003) but remains a great challenge in assisted reproduction technology.

Letrozole, a third-generation reversible aromatase inhibitor, has been tried in poor responders undergoing IVF treatment. It inhibits the aromatization of androgen into estrogen, which in turn reduces the negative feedback resulting in an increase in gonadotrophins, that is the underlying mechanism of its use in ovulation induction (Mitwally and Casper 2001). The sequential use of letrozole and gonadotrophins was reported to induce more mature follicles in intrauterine
insemination cycles (Mitwally and Casper 2002). A few studies (Goswami et al. 2004; Garcia-Velasco et al. 2005; Verpoest et al. 2006; Schoolcraft et al. 2008; Ozmen et al. 2009; Yarali et al. 2009; Davar et al. 2010) on the use of letrozole in poor ovarian responders undergoing IVF treatment have been reported but their results are not consistent.

We conducted this randomized trial to compare the sequential use of letrozole and gonadotrophin with gonadotrophin only in poor ovarian responders or women with poor ovarian reserve undergoing IVF treatment.

**Materials and Methods**

**Study population**

Subfertile patients attending Centre of Assisted Reproduction and Embryology The University of Hong Kong - Queen Mary Hospital were recruited if they had less than four oocytes retrieved in their previous failed IVF cycles or were found to have less than five antral follicles as assessed during early follicular phase within two months preceding the IVF treatment cycle. Those aged above 40 or having major medical illness such as severe hepatic or renal impairments were excluded.

Consecutive women who fulfilled the selection criteria and were willing to participate were counseled and recruited. They gave an informed written consent prior to participating in the study, which was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster. The trial was registered on the
HKClinicalTrials.com with the trial number HKCTR-1158. Subjects were recruited to join the study only once and did not receive any monetary compensation for participation in the study.

Randomization and treatment regimen

Eligible women were recruited on the second day of the treatment cycle and underwent an ultrasound scan to exclude the presence of ovarian cysts. They were then randomized according to a computer-generated randomization list in sealed, opaque envelopes into two groups: the letrozole and control groups. The sequence of allocation was concealed until interventions were assigned by the research nurse after the patients were recruited by an investigator. In the letrozole group, women received letrozole (Femara; Norvatis, East Hanover, NJ, USA) 2.5 mg daily from day 2 to day 6 for 5 days. This was followed by a fixed daily dose of intramuscular injection of 225 IU human menopausal gonadotrophin (HMG, Menogon, Ferring GmbH, Kiel, Germany) until the day of human chorionic gonadotrophin (hCG) administration. In the control group, they were given a fixed daily dose of 225 IU HMG from day 3 onwards. Ovarian response was monitored by serial transvaginal scanning and hormonal assays from day 6 onwards. Ganirelix 0.25mg (Orgalutran®, Organon) was administered when the leading follicle was ≥ 12mm in diameter. Human chorionic gonadotrophin (hCG) at a dose of 10000 IU (Profasi, Serono, Geneva, Switzerland) was given if at least one follicle was ≥ 18 mm in diameter. Oocyte retrieval was scheduled 36 hours after the hCG injection.

Oocyte retrieval was performed using a 16 gauge double-channel needle (Cook IVF, Cook, Australia) under ultrasound guidance with a 5 MHz vaginal probe fitted with a needle guide. The double-channelled needle allowed aspiration and flushing of follicles >10 mm from both ovaries. Follicular fluid of the first mature follicle on both sides not contaminated with blood was
collected for hormonal analysis using medium-free collection tubes. Each follicle was flushed once with culture media and the fluid obtained from the aspiration and flushing was examined by an embryologist. The retrieved oocytes were inseminated conventionally or by intracytoplasmic sperm injection (ICSI) as indicated. Fertilization was checked 14-18 hours after the insemination. An oocyte was considered to be normally fertilized when two pronuclei were visible. When no pronucleus or only one pronucleus was visible, the oocyte was cultured for another 3-4 hours and examined again. A maximum of two normally cleaving embryos were transferred to the uterine cavity two days after the retrieval.

Blood was taken for determination of serum estradiol (E2), progesterone (P), follicle-stimulating hormone (FSH) and luteinizing hormone (LH) concentrations on alternate days from day 2 until the day of oocyte retrieval (hCG+2). Serum E2 and P concentrations were checked on hCG+10 day. Follicular fluid was assayed for E2, P4, FSH, LH, anti-Müllerian hormone (AMH), total testosterone, androstenedione and inhibin B concentrations. The sensitivity, intra-assay and inter-assay coefficients of variation for hormonal assays were summarized in Table 1. Urine pregnancy test was performed 20 days after the ovulatory dose of hCG.

Ongoing pregnancies were those pregnancies beyond 10-12 weeks of gestation, at which stage the patients were referred out for antenatal care. Live-birth was defined as the delivery of live-birth after 24 gestational weeks.

**Outcome measures**

The primary outcome measure of the study was the number of oocytes retrieved. The secondary
outcome measures were serum and follicular fluid hormone concentrations, ongoing pregnancy rate, live-birth rate, cumulative live-birth rate including the live-births resulting from the transfer of frozen-thawed embryos, and total dosage and duration of stimulation with gonadotrophins.

**Statistical analysis**

We had shown previously that when the AFC was less than 5, the mean number of oocytes retrieved was 4.3 (Ng et al. 2000). Co-administration of letrozole improved the ovarian response from a mean number of follicles from 1.9 to 3.3 (Mitwally and Casper 2002). If the same improvement can be assumed for the number of oocytes, then co-administration of letrozole will increase the mean number of oocytes in our patients from 4.3 to 7.5. In order to detect such a difference with a power of 80% at 5% significance level, 33 patients would be needed in each group. We aimed to recruit 35 patients in each group to allow for patients who might dropout after recruitment.

The Kolmogorov-Smirnov test was used to test the normal distribution of continuous variables. Results of continuous variables were given as mean ± standard deviation (SD) if normally distributed, and as median (range) if not normally distributed. Statistical comparison was carried out by Student’s T test, Mann-Whitney U-test, Wilcoxon signed ranks test for continuous variables and chi-squared test or Fisher’s Exact Test for categorical variables, where appropriate. Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS Inc., Version 17.0, Chicago, USA). The two-tailed value of P <0.05 was considered statistically significant.
Results

Study population

During the study period between 1\textsuperscript{st} September 2005 and 30\textsuperscript{th} September 2009, 65 consecutive eligible patients were approached and 53 patients were recruited. The study was prematurely terminated before reaching the pre-defined sample size due to recruitment difficulties. Twenty-six subjects were randomized to the letrozole group while 27 subjects were in the control group. (Figure 1). There was no adverse event in both groups leading to cessation of treatment cycles.

The demographic data were shown in Table 2. There were no significant differences in age of women, duration of subfertility, body mass index, the percentage of primary subfertility, the cause of subfertility and the smoking status between the letrozole and control groups.

Outcomes

The letrozole group used a significantly lower dose of HMG and had a significantly shorter duration of HMG when compared with the control group (Table 3). The duration of GnRH antagonist was comparable in both groups. The number of oocytes retrieved was significantly lower in the letrozole group than that in the control group ($P = 0.001$) but the number of embryos transferred was similar for the two groups. The cancellation rate, implantation rate, ongoing pregnancy rate, live-birth rate and cumulative live-birth rate (23.1\% (6/26) vs 7.4\% (2/27), $p = 0.111$) were comparable for both groups. A significantly lower miscarriage rate was noted in the letrozole group than the control group (0\% vs 60\%, respectively, $p=0.038$).

Serum and follicular fluid hormonal profiles
Serum E2 concentration of the letrozole group was significantly lower than that of the control group from Day 4 to the day of hCG administration. FSH concentrations of the letrozole and control groups were comparable on most of the days, except on day 8 when the FSH concentration of the letrozole group was significantly lower than that of the control group. Serum LH concentration was significantly higher in the letrozole group than that in the control group from Day 4 to D8. (Figure 2)

Follicular fluids were collected in 36 patients (18 in the letrozole group and 18 in the control group). Follicular FSH, testosterone, androstenedione and AMH concentrations were significantly higher in the letrozole group than those in the control group (P = 0.046, P = 0.009, P = 0.001 and P =0.034 respectively; Table 4). Other hormones were similar between the two groups.
Discussion

Results of this randomized study confirmed that sequential use of letrozole and HMG in poor ovarian responders significantly reduced the total dosage and duration of HMG used. Although the number of oocytes retrieved was significantly lower in the letrozole group, the live-birth rate was similar for both groups. It was also shown that serum FSH concentrations were comparable in both groups on the majority of the days during ovarian stimulation. Follicular fluid concentrations of testosterone, androstenedione, FSH and AMH were significantly higher in the letrozole group.

The management of poor ovarian responders remains a great challenge in assisted reproduction (Shanbhag et al. 2007). An increased dose of gonadotrophin did not improve the outcome of in-vitro fertilization treatment in several studies (Land et al. 1996; Klinkert et al. 2005; Lekamge et al. 2008). Letrozole has been used in ovulation induction and ovarian stimulation (Mitwally and Casper 2001; Mitwally and Casper 2004; Badawy et al. 2009a; Badawy et al. 2009b). Mitwally and Casper (2002) in an observational study reported that a sequential regimen of letrozole and gonadotrophin in intrauterine insemination cycles was associated with a significantly lower gonadotrophin dosage but a significantly higher number of mature follicles when compared with those of previous failed cycles using gonadotrophin alone. The use of letrozole in poor ovarian responders during IVF treatment is summarized in Table 5 but results in terms of pregnancy outcomes are not consistent. Goswami et al. (2004), Garcia-Velasco et al. (2005), Ozmen et al. (2009) and Davar et al. 2010) reported a comparable pregnancy rate in the letrozole group whereas Garcia-Velasco et al. (2005) and Yarali et al. (2009) showed a higher implantation rate.
Our data confirmed the results of an early RCT with the significantly lower serum estradiol concentration and lower dosage of gonadotrophin usage (Goswami et al. 2004). We failed to demonstrate the improved implantation rate following sequential use of letrozole as shown in the prospective observational study by Garcia-Velasco et al. (2005), probably due to our small sample size. A favourable hormonal environment of the follicular fluid was reported in the same study; while our data further elaborated on the hormonal concentrations that letrozole may provide to give more favourable clinical outcomes. Although the majority of previous studies showed a comparable number of oocytes in the letrozole and control groups, our data showed a significantly lower number of oocytes retrieved in the letrozole group. This is in line with the result of Davar et al. (2010). Despite a smaller number of oocytes obtained in the letrozole group, the live-birth rate was higher, although not statistically significantly, in the letrozole group than the control group. The required sample size with adequate power to show a statistically significant difference in live birth rate would be 139 patients in each group, in total 278 women.

All the above trials used 2.5 mg letrozole daily for 5 days, either sequentially or concomitantly. A RCT using 7.5 mg letrozole in intrauterine insemination showed a non-significantly higher number of follicles than using 100 mg clomiphene citrate in women with unexplained infertility (Al-Fozan et al. 2004). There are no studies on the use of 7.5 mg or even higher dosage of letrozole in IVF treatment. The optimal dosage or duration of letrozole treatment remains unclear and requires further studies to refine it.
Another advantage of the letrozole regimen is the lower cost as a result of the lower dose of FSH used (Goswami et al. 2004). Based on our data, using letrozole in poor ovarian responders would reduce the HMG dosage by 915 IU for each patient on average. This would save 140 US dollars (about 25% reduction) in the Hong Kong setting, including the cost required for the purified urinary gonadotrophin, letrozole tablets and GnRH antagonist. If using recombinant products instead of the urinary products, the cost would drop by 32.2% (1,331 dollars to 902 dollars). In view of the comparable live-birth rate, the use of letrozole would be a more favourable protocol in poor ovarian responders.

One major concern of using letrozole in ovulation induction or ovarian stimulation is its possible teratogenicity (Biljan et al. 2005). Animal data showed embryo and fetal death in both rats and rabbits, and congenital malformation of kidneys and ureters, and altered sexual function in male offspring in rats (Rockville 2003; Gill et al. 2008). The data from humans seem to be reassuring as no congenital abnormality has been linked to the use of letrozole (Tulandi et al. 2006) which has a short half-life of 45 hours. There is a sufficient time interval for complete clearance after its administration in the early follicular phase, i.e. days 2 - 6 of the cycle in ovulation induction or ovarian stimulation, so the drug should not be present during the fertilization and implantation periods (Requena et al. 2008). In our study, there were no congenital anomalies noted in the letrozole group, while in the control group, one patient had second trimester termination of pregnancy for fetal body stalk syndrome after conceiving in the first frozen/thawed embryo transfer cycle.

Hormone concentrations
Serum E2 concentrations were significantly lower in women receiving letrozole together with gonadotrophin during ovarian stimulation in all trials (Goswami et al. 2004; Verpoest et al. 2006; Schoolcraft et al. 2008; Ozmen et al. 2009; Yarali et al. 2009; Davar et al., 2010). Our data also confirmed this. It has been shown that both the embryo quality and endometrial receptivity would be improved in a more physiological hormonal environment following a mild ovarian stimulation protocol (Devroey et al. 2004) which may explain the comparable live-birth rate in the two groups with the significantly lower number of oocytes in the letrozole group.

The baseline serum FSH concentration was comparable in both groups. Although we used the sequential regimen of letrozole and gonadotrophin, i.e. we did not give gonadotrophin during the first 5 days of stimulation, the serum FSH concentrations were comparable for the letrozole and control groups except on day 8, despite the fact that the control group received gonadotrophin from day 3 onwards. It is likely that the suppression of estrogen production by letrozole releases the negative feedback mechanism causing a rise in the gonadotrophin concentration. The serum FSH concentration rose quickly from day 2 to day 4, then plateauing afterwards, so we suggested that it may not be necessary to use gonadotrophin concomitantly with letrozole from day 2 to day 7, as used in previous studies.

Androgen was shown to be pivotal in folliculogenesis (Weil et al. 1998). Other than its action in the early stage of follicular differentiation focusing on the enhancement of FSH-stimulated follicular differentiation, a gradual transition to a later stage of folliculogenesis would result in an increase of the stimulation of FSH and LH and androgen mainly becomes a substrate for estrogen synthesis (Tetsuka and Hillier 1997). Animal studies also revealed that testosterone
augmented follicular FSH receptor expression in granulose cells suggesting that androgens promoted follicular growth and estrogen biosynthesis indirectly by amplification of the effect of FSH (Weil et al. 1999). However, there are scarce data on the effect of letrozole use on the intra-ovarian environment, except one small prospective study (Garcia-Velasco et al. 2005). As letrozole selectively blocks the conversion from androgen to estrogen by suppressing the action of aromastase, the androgen concentration in the follicular fluid would be increased. Follicular fluid testosterone concentration was reported to be lower in the poor ovarian responders (Bahceci et al. 2007), and serum androstenedione in cycles not cancelled was found to be significantly higher than that in cancelled cycles in poor ovarian responders (Balasch et al. 2006). Our data confirmed follicular fluid androgen concentrations were significantly higher in the letrozole group than that in the control group, which was consistent with those of the previous study (Garcia-Velasco et al. 2005).

One longitudinal study reported a positive correlation between the follicular fluid AMH concentration and pregnancy rate and also with the number of oocytes retrieved (Wunder et al. 2008). Follicular fluid AMH levels were positively correlated with the FSH sensitivity (Dumesic et al. 2009), and the fertilization rate (Takahashi et al. 2008). Our data showed that the follicular fluid AMH concentrations were significantly higher after the use of letrozole, which further supports the favourable hormonal profiles especially in cases of poor ovarian responders. However, the mechanism of the increase in AMH concentrations after letrozole treatment and its effect on growing follicles are still unclear.
Elevated follicular fluid levels of inhibin B and estradiol have been reported to be related to the oocyte retrieval rate, better ovarian response and higher pregnancy rate (Ocal et al. 2004; Wen et al. 2006). However, in our study, we failed to demonstrate the difference in estradiol and inhibin B level in follicular fluid between the two groups.

Limitation
One of the limitations of the present study was that we included both poor ovarian responders and those with a poor ovarian reserve as shown by a low AFC. The primary outcome was the number of oocytes obtained rather than the live-birth rate. The sample size was not large enough to show any statistical significance in the live-birth rate. The study was prematurely terminated because of recruitment difficulties. The significant difference in the miscarriage rate should be interpreted with caution as it could be a chance event.

Conclusion
Sequential use of letrozole and gonadotrophin in poor responders resulted in a significantly lower total dosage and shorter duration of gonadotrophin administration, significantly fewer oocytes retrieved but a comparable live-birth rate and a significantly lower miscarriage rate, when compared to gonadotrophin alone. Further larger trials are required to confirm the findings.

Acknowledgement
We thank all women who participated in this study and Ms Jane Chan for the coordination of the study.
References


Biljan MM, Hcmmings R, Brassard N, 2005. The outcome of 150 babies following the treatment with letrozole or lelrozole and gonadotrophins. Fertil Steril. 84(supp),1033.


Klinkert ER, Broekmans FJ, Looman CWN, Habbema JDF, Te Velde ER, 2005. Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Hum Reprod. 20,611-5.


### Table 1. Details of hormone assays

<table>
<thead>
<tr>
<th>Laboratory tests</th>
<th>Limit of detection</th>
<th>Intra-assay CV (%)</th>
<th>Inter-assay CV (%)</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estradiol (pmol/L)</td>
<td>73</td>
<td>4.0</td>
<td>5.0</td>
<td>Beckman Coulter</td>
</tr>
<tr>
<td>Progesterone (nmol/L)</td>
<td>0.25</td>
<td>4.4</td>
<td>3.6</td>
<td>Beckman Coulter</td>
</tr>
<tr>
<td>FSH (IU/L)</td>
<td>0.2</td>
<td>3.1</td>
<td>5.4</td>
<td>Beckman Coulter</td>
</tr>
<tr>
<td>LH (IU/L)</td>
<td>0.2</td>
<td>3.6</td>
<td>4.3</td>
<td>Beckman Coulter</td>
</tr>
<tr>
<td>Testosterone (ng/mL)</td>
<td>0.04</td>
<td>4.8-6.8</td>
<td>2.8-4.9</td>
<td>Immunoassay (DSL)</td>
</tr>
<tr>
<td>Androstenedione (ng/mL)</td>
<td>0.03</td>
<td>7.8-10.3</td>
<td>6.3-9.2</td>
<td>DSL</td>
</tr>
<tr>
<td>AMH (pM)</td>
<td>1</td>
<td>0-11.4</td>
<td>0-14</td>
<td>Immunotect (BC)</td>
</tr>
<tr>
<td>Inhibin B (pg/mL)</td>
<td>7</td>
<td>3.5-5.6</td>
<td>6.2-7.6</td>
<td>DSL</td>
</tr>
</tbody>
</table>

CV-coefficients of variation.  
FSH - follicle-stimulating hormone.  
LH – luteinizing hormone.  
AMH – antimullerian hormone.
Table 2. Demographic data.

<table>
<thead>
<tr>
<th></th>
<th>Letrozole group (n=26)</th>
<th>Control group (n=27)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td>37.3 ± 2.4</td>
<td>36.2 ± 2.2</td>
</tr>
<tr>
<td>Duration of subfertility (yrs)</td>
<td>5.3 ± 2.5</td>
<td>4.7 ± 2.0</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>21.0 ± 2.3</td>
<td>20.7 ± 2.1</td>
</tr>
<tr>
<td>Primary subfertility (%)</td>
<td>18 (69.2)</td>
<td>22 (81.5)</td>
</tr>
</tbody>
</table>

Cause of subfertility
- tubal                   | 6 (23.0)               | 4 (14.8)             |
- endometriosis           | 3 (11.5)               | 8 (29.6)             |
- male                    | 10 (38.5)              | 11 (40.7)            |
- unexplained             | 3 (11.5)               | 2 (7.4)              |
- mixed                   | 4 (15.4)               | 2 (7.4)              |

Smoking status           | 1 (3.8)                | 1 (3.7)              |

Data presented as mean ± standard deviation or number (percentage).
There were no statistically significant differences between the two groups.

Table 3. Comparison of outcomes.

<table>
<thead>
<tr>
<th></th>
<th>Letrozole group (n=26)</th>
<th>Control group (n=27)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dosage of gonadotrophins (IU)</td>
<td>1507.5 ± 570.0</td>
<td>2422.5 ± 435.0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Duration of stimulation (days)</td>
<td>6.4 ± 2.5</td>
<td>10.2 ± 2.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Antagonist dosage (IU)</td>
<td>4.7 ± 1.8</td>
<td>4.9 ± 2.1</td>
<td>NS</td>
</tr>
<tr>
<td>Total no of follicle aspirated</td>
<td>3.0 (0-11)</td>
<td>5.0 (0-26)</td>
<td>0.001</td>
</tr>
<tr>
<td>No of oocytes retrieved</td>
<td>2.0 (0-4)</td>
<td>4.0 (0-19)</td>
<td>0.001</td>
</tr>
<tr>
<td>No of embryos cleaveda</td>
<td>1.0 (0-3)</td>
<td>2.0 (0-15)</td>
<td>0.020</td>
</tr>
<tr>
<td>No of embryos transferreda</td>
<td>1.0 (0-2)</td>
<td>2.0 (0-3)</td>
<td>NS</td>
</tr>
<tr>
<td>Cancellation rate (due to premature luteinisation)b</td>
<td>4 (15.0%)</td>
<td>2 (7.4%)</td>
<td>NS</td>
</tr>
<tr>
<td>Cancellation rate (all causes)b</td>
<td>6 (23.1%)</td>
<td>4 (14.8%)</td>
<td>NS</td>
</tr>
<tr>
<td>Implantation rateb</td>
<td>5/23 (21.7%)</td>
<td>5/36 (13.9%)</td>
<td>NS</td>
</tr>
<tr>
<td>Ongoing pregnancy rateb</td>
<td>5 (19.2%)</td>
<td>2 (7.4%)</td>
<td>NS</td>
</tr>
<tr>
<td>Live birth rateb</td>
<td>5 (19.2%)</td>
<td>2 (7.4%)</td>
<td>NS</td>
</tr>
<tr>
<td>Miscarriage rateb</td>
<td>0 (0)</td>
<td>3/5 (60.0%)</td>
<td>0.038</td>
</tr>
</tbody>
</table>

Data were presented as mean ± standard deviation

aData were given as median (range)
bData presented as number (percentage).

NS = not statistically significant.
Table 4. Follicular fluid hormone concentrations.

<table>
<thead>
<tr>
<th></th>
<th>Letrozole group (n=18)</th>
<th>Control group (n=18)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estradiol (pmol/L)</td>
<td>1186510 (330010-2484680)</td>
<td>1012030 (518-4799080)</td>
<td>NS</td>
</tr>
<tr>
<td>Progesterone (nmol/L)</td>
<td>45313 (9442-62351)</td>
<td>45230 (38-58016)</td>
<td>NS</td>
</tr>
<tr>
<td>FSH (IU/L)</td>
<td>11.4 (6.0-16.2)</td>
<td>9.0 (5.3-121.5)</td>
<td>0.046</td>
</tr>
<tr>
<td>LH (IU/L)</td>
<td>1.0 (0.1-4.6)</td>
<td>0.4 (0.1-6.4)</td>
<td>NS</td>
</tr>
<tr>
<td>Testosterone (ng/mL)</td>
<td>19.2 (9.4-53.0)</td>
<td>9.0 (2.1-52.4)</td>
<td>0.009</td>
</tr>
<tr>
<td>Androstenedione (ng/mL)</td>
<td>10.8 (3.5-234.1)</td>
<td>5.0 (2.4-370.1)</td>
<td>0.001</td>
</tr>
<tr>
<td>AMH (pM)</td>
<td>3.0 (1.2-45.8)</td>
<td>1.9 (0.8-5.1)</td>
<td>0.034</td>
</tr>
<tr>
<td>Inhibin B (pg/mL)</td>
<td>390.3 (31.3-2568.3)</td>
<td>321.4 (0-1114.6)</td>
<td>NS</td>
</tr>
</tbody>
</table>

Data presented as median (range).
AMH-anti-Müllerian hormone, NS = not statistically significant.
Table 5. Summary of studies using letrozole in poor ovarian responders during in-vitro fertilisation treatment.

<table>
<thead>
<tr>
<th>Study</th>
<th>Protocol</th>
<th>No of women</th>
<th>Days of FSH</th>
<th>FSH dosage (IU)</th>
<th>ET (mm)</th>
<th>E2 (pg/ml)</th>
<th>No of eggs</th>
<th>IR (%)</th>
<th>PR (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GnRHa long protocol</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Goswami et al., 2004 (RCT)</td>
<td></td>
<td>13</td>
<td>-</td>
<td>150 (0)</td>
<td>8.5 (0.4)</td>
<td>227 (45)</td>
<td>1.6 (0.8)</td>
<td>-</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rFSH</td>
<td>-</td>
<td>2865 (228)</td>
<td>7.4 (0.4)</td>
<td>380 (46)</td>
<td>2.1 (0.7)</td>
<td>-</td>
<td>24</td>
</tr>
<tr>
<td><strong>Antagonist protocol</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Garcia-Velasco et al., 2005 (Prospective Observational)</td>
<td></td>
<td>71</td>
<td>9.3 (0.3)</td>
<td>3627 (116)</td>
<td>9.6 (0.5)</td>
<td>770 (67)</td>
<td>6.1 (0.4)</td>
<td>25</td>
<td>22.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rFSH</td>
<td>8.9 (0.2)</td>
<td>3804 (127)</td>
<td>9.8 (0.3)</td>
<td>813 (60)</td>
<td>4.3 (0.3)</td>
<td>9.4</td>
<td>15.2</td>
</tr>
<tr>
<td>Verpoest et al., 2006 (RCT)</td>
<td></td>
<td>10</td>
<td>-</td>
<td>-</td>
<td>10.3</td>
<td>-</td>
<td>13.8 (9.2)</td>
<td>31.3</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rFSH</td>
<td>-</td>
<td>-</td>
<td>8.1</td>
<td>-</td>
<td>9.6 (7.7)</td>
<td>12.5</td>
<td>20</td>
</tr>
<tr>
<td><strong>Ozmen et al., 2009 (RCT)</strong></td>
<td></td>
<td>35</td>
<td>-</td>
<td>2980 (435)</td>
<td>9.3 (2.6)</td>
<td>1870 (159)</td>
<td>4.9 (1.6)</td>
<td>-</td>
<td>25.8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rFSH</td>
<td>-</td>
<td>3850 (580)</td>
<td>9.7 (3.2)</td>
<td>2015 (175)</td>
<td>4.8 (1.4)</td>
<td>-</td>
<td>20</td>
</tr>
<tr>
<td><strong>Microflare protocol</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schoolcraft et al., 2008 (Prospective)</td>
<td></td>
<td>179</td>
<td>9.9 (1.3)</td>
<td>4223 (743)</td>
<td>-</td>
<td>1403 (965)</td>
<td>12 (6)</td>
<td>15</td>
<td>37</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GnRHa +rFSH</td>
<td>10.1 (1.6)</td>
<td>3938 (975)</td>
<td>-</td>
<td>3147 (1189)</td>
<td>13 (5.3)</td>
<td>21</td>
<td>52</td>
</tr>
<tr>
<td>Yarali et al., 2009 (Retrospective)</td>
<td></td>
<td>212</td>
<td>9.0 (2.5)</td>
<td>4020 (1178)</td>
<td>9.7 (2.4)</td>
<td>794 (711)</td>
<td>4.1 (3.4)</td>
<td>14.5</td>
<td>22.8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GnRHa +rFSH</td>
<td>10.2 (4.0)</td>
<td>4538 (1493)</td>
<td>10.1 (2.5)</td>
<td>1805 (1228)</td>
<td>6.7 (4.5)</td>
<td>9.8</td>
<td>17.4</td>
</tr>
<tr>
<td><strong>Davar et al., 2010 (RCT)</strong></td>
<td></td>
<td>45</td>
<td>8.5 (1.1)</td>
<td>3158 (563)</td>
<td>8.3 (1.3)</td>
<td>477 (54)</td>
<td>2.8 (2.7)</td>
<td>3.8</td>
<td>5.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GnRHa +FSH</td>
<td>9.2 (1.2)</td>
<td>3458 (533)</td>
<td>8.4 (1.2)</td>
<td>1065 (706)</td>
<td>4.4 (2.7)</td>
<td>7.7</td>
<td>14.3</td>
</tr>
</tbody>
</table>


\(^a p<0.05\)
Figure 1. Flow diagram of patient participation in the trial.

Figure 2. Serum hormone concentrations on various days of ovarian stimulation. Panel 2a, oestradiol concentrations of the letrozole group were significantly lower than the control group from day 4 to the day of hCG (all p-values < 0.001). Panel 2b, FSH concentrations of the letrozole and control groups were comparable on most the days, except on day 8 when FSH concentration of the letrozole group was significantly lower than that of the control group (p <0.001). Panel 2c, LH concentrations of the letrozole group were significantly higher than the control groups on days 4, 6 and 8 (p 0.018, <0.001 and 0.018 respectively).